Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bocodepsin · OKI-179, OKI-006

Small molecule · Inhibitor of histone deacetylase 1 (HDAC1) and histone deacetylase 4 (HDAC4) · developed by OnKure

Phase 1/2 Most advanced trial (none active)
OKUR Developer
2 Registered trials

What is Bocodepsin?

Bocodepsin is an orally bioavailable inhibitor of histone deacetylase subtypes 1 and 4 (HDAC1/4). By blocking these enzymes it increases chromatin histone acetylation, altering gene expression and inducing apoptosis in tumor cells that overexpress HDAC1/4. It is being studied in advanced solid tumors, including NRAS-mutated melanoma, in combination with binimetinib.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OKI-179, OKI-006
Drug type
Small molecule
Targets
histone deacetylase 1 (HDAC1), histone deacetylase 4 (HDAC4)
Mechanism
Inhibitor of histone deacetylase 1 (HDAC1) and histone deacetylase 4 (HDAC4)
Pathways
histone acetylation and chromatin remodeling, tumor suppressor gene transcription, cell cycle progression, apoptosis
Therapy area
Oncology
Developer
OnKure, Inc. (OKUR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
K5D067O1SW

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05340621 Phase 1/2 RAS Mutation Completed OKUR
NCT03931681 Phase 1 Advanced Solid Tumors Completed OKUR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsMelanomaNRAS Gene MutationRAS Mutation

Other drugs acting on HDAC1 / HDAC4

More from OnKure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OKUR page.

Follow OKUR, the company behind Bocodepsin

See OKUR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OKUR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.